Nabi And Roxane In Patent Dispute Over Kidney Dialysis Drug

Law360, New York (September 29, 2005, 12:00 AM EDT) -- Nabi Biopharmaceuticals has sued to Roxane Laboratories to prevent the company from making a generic version of kidney dialysis drug PhosLo.

Roxane sent Nabi a letter on August 8, 2005 informing the drug company that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration to make a generic version of PhosLo.

The lawsuit claims that “the letter did not provide the information specified by the FDA regulations. Nor did it demonstrate that the ‘665 patent is either invalid or would...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.